Golden, Colorado—November 12, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced an interview of its CEO by Juan Costello of the Wall Street Analyst http://wallstreetanalyzer.com/vitro-diagnostics-otcbbvodg-ceo-interview). In the interview, our CEO elaborated on the effect of its planned merger with Neuromics, Inc. in greater detail and provided an overview of the near-term plans to accelerate growth. Completion of the merger would immediately expand revenues from research products by several-fold. While Vitro Biopharma’s research products are primarily focused on adult stem cells and related products, the addition of Neuromics product lines expands our offerings to include antibodies, an expansive number of products for proteomics, apoptosis (cell death) assays, molecular biology reagents, together with numerous cell-based assay products complementary to Vitro’s stem cell-based products.
In addition, Vitro Biopharma is developing a pipeline of products for use in drug discovery, development and toxicology based on stem cell-derived cell-based assays that replicate in-vivo cellular systems for high throughput analysis of key parameters. From the interview, Dr. Jim Musick, Vitro Biopharma’s CEO said, “Our uniqueness is that the cellular systems that we’re analyzing truly reflect what’s happening in the body because we use not only the drug target cells themselves and the media that the cells live in, but also proper extracellular matrices, the materials outside of the cells. All components are provided in high throughput configuration including an automated live cell assay system together with advanced digital read-out capabilities. We’ve recently purchased a new instrument that will allow us to generate the data needed to pursue this area.”
Additional growth prospects for revenue growth are presented in detail within the Wall Street Analyst interview (http://wallstreetanalyzer.com/vitro-diagnostics-otcbbvodg-ceo-interview).
About Vitro Biopharma
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro Biopharma also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro Biopharma’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation. In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com). Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems We jointly manufacture stem cell assay systems with HemoGenix®, Inc. (http://www.hemogenix.com/), known as the MSCglo quantitative assay for determination of MSC quality, potency and response to toxic agents. Also, Vitro Biopharma’s CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.
About Neuromics, Inc.
Neuromics (http://www.neuromics.com), located in Minneapolis, MN, is a privately-held, profitable and growing bio-reagents company. The company was initially built by supplying bio-markers to Neuroscience Researchers. Today, Neuromics provides a range of solutions that include markers, growth factors, gene expression analysis tools, apoptosis detection kits, primary cells, stem cells and related media. These solutions are increasingly being used in combinations by customers to help accelerate or improve the process of drug discovery.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
Dr. James Musick
Chief Executive Officer
(303) 999-2130 Ext. 3
Source: Vitro Diagnostics, Inc.